CAST - Active Monitoring of Cancer As An Alternative To Surgery

When a patient is discovered to have cancer, one of the primary goals is to have the tumour removed by surgery. Although
this provides excellent oncological control, it is associated with morbidity and functional problems in cancer survivors. Recent
studies have shown that the immediacy to perform a resection does not always lead to improved clinical outcome.
Furthermore, cancer surgery can often lead to complications where the quality of life for the patient is compromised by toxic
side effects and /or damage to nerves, organs or healthy tissues. A number of recent clinical trials in the field of cancer
surgery have advocated the concept of watch and wait, watchful waiting, active monitoring or surveillance, which are terms
used to describe a monitoring strategy for cancer. The concept may be antithetical but the functional advantage of these
alternatives is clear even though there is some concern about the risk. Though the evidence is still weak, current studies
suggest that with adequate selection and follow-up, this oncological risk is small. A major consideration for clinicians is now
to maintain quality of life for all patients. Our objective in this proposal is to implement novel approaches so that cancer
surgery can be avoided, where we aim to (a) develop new monitoring technologies from industry so that the surveillance
window can be increased to allow for better treatment options over time and to avoid surgery, (b) develop new ‘watch and
wait’ strategies in order to study the behaviour of the cancer so that any risks to the patient can be minimised leading to a
better clinical outcome and (c) train a new generation of preclinical and clinical scientists to be able to implement this new
concept as standard of care and to maximise the benefits of an active monitoring policy.

Coordinator: ACADEMISCH ZIEKENHUIS  LEIDEN The Netherlands

Start Date:2019-11-01 / End Date: 2023-10-31

Info at Cordis: https://cordis.europa.eu/project/id/857894

Acronimo: 
CAST
Soggetto finaziatore: 
Unione Europea
Programma di Finanziamento e bando: 
H2020-MSCA-ITN-2019 / MSCA-ITN-ETN
Numero del progetto/Contratto: 
857894
Responsabile Scientifico: 
Prof.sa Piera Di Martino
ruolo Unicam: 
Partner
Partner: 
Nome: 
ACADEMISCH ZIEKENHUIS LEIDEN
Tipologia: 
Università
Stato: 
The Netherlands
Ruolo: 
Coordinator
Nome: 
UNIVERSITE DE STRASBOURG
Tipologia: 
Università
Stato: 
France
Ruolo: 
Partner
Nome: 
KAROLINSKA INSTITUTET
Tipologia: 
Ente di Ricerca
Stato: 
Sweden
Ruolo: 
Partner
Nome: 
FUNDACAO D. ANNA SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD
Tipologia: 
Fondazione - Ente di Ricerca
Stato: 
Portugal
Ruolo: 
Partner
Nome: 
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Tipologia: 
Ente di Ricerca
Stato: 
The Netherlands
Ruolo: 
Partner
Nome: 
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Tipologia: 
Università
Stato: 
Germany
Ruolo: 
Partner
Nome: 
The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
Tipologia: 
Ente di Ricerca
Stato: 
Poland
Ruolo: 
Partner
Nome: 
THE UNIVERSITY OF LIVERPOOL
Tipologia: 
Università
Stato: 
United Kingdom
Ruolo: 
Partner
Nome: 
THE UNIVERSITY OF MANCHESTER
Tipologia: 
Università
Stato: 
United Kingdom
Ruolo: 
Partner
Nome: 
PERCUROS BV
Tipologia: 
Azienda
Stato: 
The Netherlands
Ruolo: 
Partner
Nome: 
SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH
Tipologia: 
Azienda
Stato: 
Germany
Ruolo: 
Partner
Nome: 
Surgimab SAS
Tipologia: 
Azienda
Stato: 
France
Ruolo: 
Partner
Nome: 
Edinburgh Molecular Imaging Ltd
Tipologia: 
Azienda
Stato: 
United Kingdom
Ruolo: 
Partner
Tipo di finaziamento: 
Horizon 2020